| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $326.17 | $2,348,425.50 | -22.5% | +23.8% | -3.6% | |
| Aug 13, 2024 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 11,570 | $150.43 | $1,740,449.65 | -8.9% | -15.6% | -12.7% | |
| Aug 13, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 7,143 | $150.10 | $1,072,180.44 | -43.9% | -15.6% | -12.7% | |
| Aug 13, 2024 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 5,154 | $28.66 | $147,713.64 | -37.5% | -9.0% | -12.8% | |
| Aug 13, 2024 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 14,100 | $150.38 | $2,120,346.72 | -30.9% | -15.6% | -12.7% | |
| Aug 13, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 250 | $59.62 | $14,905.00 | -0.4% | +4.7% | +50.5% | |
| Aug 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 3,107 | $4.27 | $13,266.89 | -1.9% | +12.7% | -76.8% | |
| Aug 12, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 98,943 | $17.30 | $1,711,446.75 | -100% | +1.7% | -2.8% | |
| Aug 12, 2024 | PCRX Pacira Biosciences, Inc. | Froimson Mark72 | Director | Buy | 1,400 | $11.58 | $16,212.00 | +10.7% | +42.4% | +101.9% | |
| Aug 12, 2024 | PCRX Pacira Biosciences, Inc. | Bigal Marcelo82 | Director | Buy | 3,400 | $12.01 | $40,834.00 | +65.0% | +42.4% | +101.9% | |
| Aug 12, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 17,101 | $43.07 | $736,550.33 | -33.5% | +12.3% | -29.8% | |
| Aug 12, 2024 | LNTH Lantheus Holdings, Inc. | Ber Gerard | Director | Sell | 15,500 | $96.48 | $1,495,395.75 | -18.5% | -13.0% | -44.2% | |
| Aug 12, 2024 | ELAN Elanco Animal Health Inc | Simmons Jeffrey N52 | President, CEO And Director | Buy | 100,000 | $13.01 | $1,300,610.00 | +222.2% | +9.0% | +33.2% | |
| Aug 12, 2024 | IRWD Ironwood Pharmaceuticals Inc | John Minardo69 | Chief Legal Officer | Sell | 9,910 | $4.27 | $42,315.70 | -3.4% | +12.7% | -76.8% | |
| Aug 12, 2024 | PCRX Pacira Biosciences, Inc. | Lee Frank D. | Chief Executive Officer | Buy | 8,264 | $12.10 | $99,994.40 | +8.3% | +42.4% | +101.9% | |
| Aug 12, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $332.31 | $2,392,620.92 | -30.0% | +20.0% | -9.7% | |
| Aug 9, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "remarks" | Sell | 45,060 | $17.38 | $782,971.57 | -100% | +0.4% | -6.1% | |
| Aug 9, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Grant Angus | EVP, Business Development | Sell | 4,065 | $17.28 | $70,243.20 | -31.5% | +0.4% | -6.1% | |
| Aug 8, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 20,524 | $0.16 | $3,283.84 | +2.1% | - | - | |
| Aug 8, 2024 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | President | Sell | 2,000 | $96.39 | $192,780.00 | -2.0% | -6.3% | -41.2% | |
| Aug 8, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $326.20 | $2,348,641.20 | -27.3% | +20.1% | -8.9% | |
| Aug 7, 2024 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 25,000 | $323.38 | $8,084,473.01 | -40.7% | +18.8% | -7.1% | |
| Aug 7, 2024 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 50,217 | $16.86 | $846,808.74 | -1.7% | +28.7% | +218.3% | |
| Aug 6, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,334 | $17.30 | $40,378.20 | -1.4% | +23.0% | +202.9% | |
| Aug 6, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 273 | $147.70 | $40,322.10 | -4.0% | -17.2% | -11.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.